直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 118462
タイトル別表記
Genomewide methylation profiling identifies a novel gene signature for patients with synchronous colorectal cancer
Methylation signature for synchronous CRC
著者
岡田, 泰行 Beckman Research Institute of City of Hope|Tokushima University 徳島大学 教育研究者総覧
Peng, Fuduan University of California Irvine
Perea, José Fundación Jiménez Díaz University Hospital
Corchete, Luis University Hospital of Salamanca|Institute of Biomedical Research of Salamanca|Cancer Research Center|Center for Biomedical Research in Network of Cancer
Bujanda, Luis Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas|Universidad del País Vasco
Li, Wei University of California Irvine
Goel, Ajay Beckman Research Institute of City of Hope|City of Hope Comprehensive Cancer Center
キーワード
synchronous colorectal cancer
gene methylation
predictive biomarker
資料タイプ
学術雑誌論文
抄録
Background: There are no robust tools for the diagnosis of synchronous colorectal cancer (SyCRC). Herein, we developed the first methylation signature to identify and characterize patients with SyCRC.
Methods: For biomarker discovery, we analyzed the genome-wide methylation profiles of 16 SyCRC and 18 solitary colorectal cancer (SoCRC) specimens. We thereafter established a methylation signature risk-scoring model to identify SyCRC in an independent cohort of 38 SyCRC and 42 SoCRC patients. In addition, we evaluated the prognostic value of the identified methylation profile.
Results: We identified six differentially methylated CpG probes/sites that distinguished SyCRC from SoCRC. In the validation cohort, we developed a methylation panel that identified patients with SyCRC from not only larger tumor (AUC=0.91) but also the paired remaining tumor (AUC=0.93). Moreover, high risk scores of our panel were associated with the development of metachronous CRC among patients with SyCRC (AUC=0.87) and emerged as an independent predictor for relapse-free survival (hazard ratio=2.72; 95% CI=1.12–6.61). Furthermore, the risk stratification model which combined with clinical risk factors was a diagnostic predictor of recurrence (AUC=0.90).
Conclusions: Our novel six-gene methylation panel robustly identifies patients with SyCRC, which has the clinical potential to improve the diagnosis and management of patients with CRC.
掲載誌名
British Journal of Cancer
ISSN
00070920
15321827
cat書誌ID
AA00574355
出版者
Springer Nature
128
1
開始ページ
112
終了ページ
120
発行日
2022-11-01
備考
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use (https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms), but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1038/s41416-022-02033-9
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
著者版
部局
病院